Clinical Trial Update: A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) [Phase 1, Phase 2]

View source ↗

Summary

LAT010 is being studied in a first-in-human, phase 1/2 trial for patients with advanced solid tumors, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• LAT010

Snippet

Sponsor: Latticon Antibody Therapeutics, Inc | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING